{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:59:43Z","timestamp":1790639983986,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012893","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000}}],"reference-count":54,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012893.pub2","type":"journal-article","created":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T15:50:18Z","timestamp":1567439418000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Certolizumab pegol for induction of remission in Crohn's disease"],"prefix":"10.1002","volume":"2019","author":[{"given":"Hajime","family":"Yamazaki","sequence":"first","affiliation":[{"name":"School of Public Health in the Graduate School of Medicine, Kyoto University; Department of Healthcare Epidemiology; Yoshida Konoe-cho, Sakyo-ku Kyoto Japan 606-8501"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuhei","family":"So","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine\/School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Toho University Sakura Hospital; Division of Gastroenterology and Hepatology, Department of Internal Medicine; 564-1 Shimoshizu Chiba Japan 2858741 Sakura"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Kitasato University Kitasato Institute Hospital; Center for Advanced IBD Research and Treatment; 5-9-1, Shirokane, Minato-ku Tokyo Japan 108-8642"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Shinzaki","sequence":"additional","affiliation":[{"name":"Osaka University Graduate School of Medicine; Department of Gastroenterology and Hepatology; Box K1, 2-2 Yamadaoka Suita Osaka Japan 565-0871"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Kyoto University Hospital; Department of Gastroenterology and Hepatology; 54 Shogoin Kawaharacho, Sakyo-ku Kyoto Japan 606-8507"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Okabayashi","sequence":"additional","affiliation":[{"name":"Kitasato University Kitasato Institute Hospital; Center for Advanced IBD Research and Treatment; 5-9-1, Shirokane, Minato-ku Tokyo Japan 108-8642"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Hyogo Prefectural Amagasaki General Medical Center; Department of Respiratory Medicine; 2-17-77, Higashi-Naniwa-Cho Amagasaki Hyogo Japan 660-8550"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"School of Public Health in the Graduate School of Medicine, Kyoto University; Department of Healthcare Epidemiology; Yoshida Konoe-cho, Sakyo-ku Kyoto Japan 606-8501"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshi A","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine\/School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine\/School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"10.1002\/14651858.CD012893.pub2-BIB0001|cit1","unstructured":"NCT00291668 Clinical study of CDP870\/Certolizumab Pegol in patients with active Crohn's disease https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00291668"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0002|cit2","unstructured":"Ogata H Ito H Motoya S Takazoe M Suzuki Y Matsumoto T Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn\u2019s disease: Results from induction and maintenance studies Gut 2009 A170"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0003|cit3","unstructured":"NCT00152490 A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00152490"},{"issue":"3","key":"10.1002\/14651858.CD012893.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0005|cit5","unstructured":"Sandborn WJ Feagan BG Stoinov S Honiball PJ Rutgeerts P McColm JA Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo controlled phase III study (PRECiSE 1) Gastroenterology 2006 A107 8"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0006|cit6","unstructured":"EUCTR-001913-41 A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn\u2019s disease https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2007-001913-41"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0007|cit7","unstructured":"NCT00552058 Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT00552058"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Sandborn W Schreiber S Feagan B Rutgeerts P Younes Z Bloomfield R Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo-controlled trial American Journal of Gastroenterology 2010 S419","DOI":"10.14309\/00000434-201010001-01156"},{"issue":"8","key":"10.1002\/14651858.CD012893.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cgh.2011.04.031","article-title":"Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial","volume":"9","author":"Sandborn","year":"2011","journal-title":"Clinical Gastroenterology & Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012893.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00384-007-0395-7","article-title":"Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease","volume":"23","author":"Rutgeerts","year":"2008","journal-title":"International Journal of Colorectal Disease"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Schreiber S Rutgeerts P Fedorak R Khaliq-Kareemi M Kamm MA Patel J CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD) Gastroenterology 2003 A61","DOI":"10.1016\/S0016-5085(03)80301-3"},{"issue":"3","key":"10.1002\/14651858.CD012893.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Colombel JF Hebuterne X Endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the music clinical trial American Journal of Gastroenterology 2008 S432","DOI":"10.14309\/00000434-200809001-01107"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0014|cit14","unstructured":"NCT00297648 Mucosal healing study in Crohn's disease (CD) (MUSIC) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00297648"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0015|cit15","unstructured":"NCT00152425 Study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo), following 3 doses of active drug (CDP870) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00152425"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0016|cit16","unstructured":"NCT00307931 Certolizumab pegol for treatment of adult Greek patients with moderate to severe Crohn's disease who failed infliximab https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00307931"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0017|cit17","unstructured":"NCT00349752 Corticosteroid sparing effect of certolizumab in Crohn's disease (COSPAR1) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00349752"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0018|cit18","unstructured":"NCT00354367 Evaluate efficacy of certolizumab in Crohn's patients with draining fistulas https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00354367"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0019|cit19","unstructured":"NCT01024647 Optimizing cimzia in Crohn's patients https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01024647"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0020|cit20","unstructured":"NCT01053559 Assessment of small bowel healing in Crohn's disease patients treated with cimzia using wireless capsule endoscopy https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01053559"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0021|cit21","unstructured":"NCT01582568 EUS evaluation of perianal and peri-rectal fistulizing Crohn's disease with CERTOLIZUMAB treatment (EUS) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01582568"},{"issue":"7","key":"10.1002\/14651858.CD012893.pub2-BIB0022|cit22","first-page":"467","article-title":"Certolizumab pegol for moderate-to-severe Crohn's disease","volume":"4","author":"Sandborn","year":"2008","journal-title":"Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Sandborn W.J Younes ZH Pierre-Louis B D'Haens GR Efficacy of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease not in remission following active or placebo induction Gastroenterology 2012 S565","DOI":"10.1016\/S0016-5085(12)62172-6"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0024|cit24","unstructured":"NCT00308581 Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00308581"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Vermeire S. Abreu MT. D'Haens G Colombel JF Mitchev K Fedorak R Efficacy and safety of certolizumab pegol in patients with active Crohn\u2019s disease who previously lost response or were intolerant to infliximab: open-label induction preliminary results of the Welcome study Gastroenterology 2008 A67 68","DOI":"10.1016\/S0016-5085(08)60318-2"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2036.2004.02285.x","article-title":"Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study","volume":"20","author":"Winter","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2036.2007.03276.x","article-title":"Meta-analysis: mortality in Crohn's disease","volume":"25","author":"Canavan","year":"2007","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointestinal Endoscopy"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/ajg.2014.297","article-title":"Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies","volume":"109","author":"Frolkis","year":"2014","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn's Disease 2016: Part 1: diagnosis and medical management","volume":"11","author":"Gomollon","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0016-5085(89)80080-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0038|cit38","article-title":"Chapter 8: Assesing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"765","DOI":"10.5114\/aoms.2013.38670","article-title":"Tumor necrosis factor-alpha antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis","volume":"9","author":"Kawalec","year":"2013","journal-title":"Archives of Medical Science"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gut.30.7.983","article-title":"Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)","volume":"30","author":"Mary","year":"1989","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMct1209614","article-title":"Tumor necrosis factor inhibitors for inflammatory bowel disease","volume":"369","author":"Nielsen","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2016.01.001","article-title":"Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases","volume":"159","author":"Olesen","year":"2016","journal-title":"Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn's disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","article-title":"Predictability of the postoperative course of Crohn's disease","volume":"99","author":"Rutgeerts","year":"1990","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD012893.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/1756283X11413315","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"4","author":"Schreiber","year":"2011","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0048|cit48","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2036.2009.03929.x","article-title":"Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease","volume":"29","author":"Shao","year":"2009","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012893.pub2-BIB0050|cit50","first-page":"S2-25; quiz S26","article-title":"An evidence-based systematic review on medical therapies for inflammatory bowel disease","volume":"106","author":"Talley","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","article-title":"American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease","volume":"145","author":"Terdiman","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012893.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","article-title":"Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity","volume":"8","author":"Vermeire","year":"2010","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012893.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Medical Care"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012893.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T09:04:12Z","timestamp":1646816652000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012893.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012893.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,29]]}}}